Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis

  • Wan-li He ,

    Contributed equally to this work with: Wan-li He, Fei-xia Chang

    Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft

    Affiliation Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China

    ⨯
  • Fei-xia Chang ,

    Contributed equally to this work with: Wan-li He, Fei-xia Chang

    Roles Conceptualization, Data curation, Investigation, Methodology, Writing – original draft

    Affiliation Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China

    ⨯
  • Tao Wang,

    Roles Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing

    Affiliation Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China

    ⨯
  • Bi-xia Sun,

    Roles Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China

    ⨯
  • Rui-rong Chen,

    Roles Methodology, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital, Lanzhou, Gansu, China

    ⨯
  • Lian-ping Zhao

    Roles Data curation, Project administration, Visualization, Writing – original draft, Writing – review & editing

    zlpzxzz@163.com

    Affiliation Department of Radiology, Gansu Provincial Hospital, Lanzhou, Gansu, China

    ⨯

Abstract

Objective

To compare the serum levels of brain-derived neurotrophic factor (BDNF) in type 2 diabetes mellitus (T2DM) patients with healthy controls (HC) and evaluate the BDNF levels in T2DM patients with/without cognitive impairment.

Methods

PubMed, EMBASE, and the Cochrane Library databases were searched for the published English literature on BDNF in T2DM patients from inception to December 2022. The BDNF data in the T2DM and HC groups were extracted, and the study quality was evaluated using the Agency for Healthcare Research and Quality. A meta-analysis of the pooled data was conducted using Review Manager 5.3 and Stata 12.0 software.

Results

A total of 18 English articles fulfilled with inclusion criteria. The standard mean difference of the serum BDNF level was significantly lower in T2DM than that in the HC group (SMD: -2.04, z = 11.19, P <0.001). Besides, T2DM cognitive impairment group had a slightly lower serum BDNF level compared to the non-cognitive impairment group (SMD: -2.59, z = 1.87, P = 0.06).

Conclusion

BDNF might be involved in the neuropathophysiology of cerebral damage in T2DM, especially cognitive impairment in T2DM.

Citation: He W-l, Chang F-x, Wang T, Sun B-x, Chen R-r, Zhao L-p (2024) Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis. PLoS ONE 19(4): e0297785. https://doi.org/10.1371/journal.pone.0297785

Editor: Purvi Purohit, All India Institute of Medical Sciences, INDIA

Received: July 25, 2023; Accepted: January 12, 2024; Published: April 22, 2024

Copyright: © 2024 He et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a chronic systemic metabolic disorder seriously affecting human health, which is triggered by genetic predisposition and environmental factors [1]. International Diabetes Federation estimates that T2DM occurs in over 400 million people and it is one of the largest epidemics worldwide [2]. T2DM manifesting through fasting and post-prandial hyperglycemia can induce various life-threatening co-morbidities and complications such as diabetic neuropathy and diabetic nephropathy [3,4]. Cognitive dysfunction is an important complication observed in type T2DM patients [5]. In addition, T2DM is an important risk factor implicated in cognitive deficits except aging and neurodegenerative disorder [6]. T2DM patients have a greater decline in cognitive function than those without T2DM [7]. Besides, it is reported that T2DM accelerates brain aging and cognitive decline [8]. T2DM is significantly associated with an increased risk of dementia and a large portion of T2DM patients with cognitive impairment eventually progress to dementia [9,10], which may represent a consequence of brain-specific insulin resistance and impaired glucose regulation [11]. However, the pathophysiological mechanisms of cerebral impairment in T2DM remain elucidated.

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophic family of proteins, is most widely distributed in the central nervous system (CNS) [12]. It plays an important role in protecting neurons and synaptic activity [13]. BDNF was released from the brain to peripheral circulation [14], and there is a correlation between BDNF in serum and CNS, providing an alternative measure of BDNF changes [15]. Alternation of BDNF is observed in the pathophysiological basis of many neurodegenerative and psychiatric disorders [16], including Alzheimer’s disease and depression [17,18]. Furthermore, the serum BDNF is a useful biomarker for executive cognitive impairment in schizophrenia patients [19,20]. In addition, the BDNF Val66Met polymorphism may be a major factor in the susceptibility to cognitive impairment which affects the secretion of mature BDNF [21]. A meta-analysis suggests that BDNF Val66Met is associated with cognitive impairment in Parkinson’s disease [22], confirming that BDNF is a risk factor for this disorder [23]. Furthermore, BDNF is related to the regulation of glucose levels [24]. Exogenous BDNF reduces blood glucose concentrations and glycated hemoglobin in obese diabetic mice [25], which is consistent with the finding that there was a positive correlation between BDNF and insulin sensitivity [26]. Previous studies have revealed the relationship between serum BDNF and diabetic conditions in T2DM patients with controversial results [27–34]. However, the precise role of BDNF in the development of T2DM patients as well as in cognitive function remains unclear.

Therefore, our study aims to explore the alteration tendency of the serum BDNF levels in T2DM patients with or without cognitive impairment using meta-analysis with a comprehensive evaluation of relevant literature. The current study will provide a basic foundation for further investigating the neuropathophysiological mechanisms of cerebral damage in T2DM.

2. Methods

2.1. Literature search and selection

A systemic search strategy was used to identify the relevant studies published in PubMed, EMBASE, and the Cochrane Library from inception to December 2022. We applied a search strategy based on the combination of relevant terms. Two independent investigators acquired articles and sequentially screened their titles and abstracts for eligibility. Then, full texts of articles deemed potentially eligible were acquired. Any disagreement would be solved via discussion with the help of a third senior investigator. A screening guide was used to ensure that the selection criteria were constantly applied.

Inclusion criteria: (1) clinical cross-sectional studies concerning the quantitative values of serum BDNF level in T2DM patients; (2) sufficient data were available for mean and standard deviation analysis of BDNF level; (3) original research. Exclusion criteria: (1) review, abstracts only, letters, comments, guidelines, and case reports; (2) studies in vitro or in animal models; (3) duplicate publications; (4) incomplete data.

2.2. Quality evaluation and data extraction

Agency for Healthcare Research and Quality (AHRQ) was used to evaluate the quality of the included cross-sectional studies. The AHRQ included 8 items with a total score of 8 points. Two independent researchers assessed the quality of the literature and reached a consensus after consultation when necessary.

The serum BDNF values (ng/ml) were extracted, and the indicators were represented by . Basic information includes the author of the document, year of publication, sample size, population distribution, country, diagnostic criteria, and measurement methods of BDNF. When standard deviations were unreported, they were calculated according to confidence interval (95% or 99%), or interquartile range or P-value. The calculation process was as follows:

Calculate standard deviation from confidence interval:

(2) Calculate the standard deviation from an interquartile range:

(3) Calculate standard deviation by p-value:

2.3. Statistical analysis

All the meta-analyses were performed on Review Manager 5.3 and STATA12.0 with a significance level of P <0.05. To calculate the effect size for each study, the summary standard mean difference (SMD) and 95% confidence interval were applied to evaluate the serum BDNF values between T2DM and healthy control (HC), T2DM with or without cognitive impairment. Pooled SMD and corresponding 95% confidence interval were calculated using the inverse variances method. Heterogeneity was estimated using the Cochran Q (P) and the inconsistency index where a P value less than 0.05 and I2 value greater than 50% indicated the presence of significant heterogeneity across the enrolled studies. If notable heterogeneity was observed, a random-effect model was applied and subgroup analyses were used to determine factors that contributed to the heterogeneity and to explore how those factors influenced the results. Subgroup analysis was stratified by the BDNF measuring instruments brand (China or USA; same brand in China or USA), ethnicity (Asian or European), and population [adults or the aged (years≥60)]. In addition, sensitivity analysis was performed to evaluate the reliability of included studies using STATA 12.0. The Egger’s test and the Begg’s test were applied to evaluate potential publication bias using STATA 12.0.

3. Results

3.1. Search and selection results

The main search strategy is illustrated in Table 1. Studies selection was managed using EndNote X7. A total of 678 records were initially identified, but only 501 records remained after the elimination of duplicates. Only 51 records were remaining after screening titles, and subsequently, 29 records remained after reading the abstract. After reading full texts, 11 articles with incomplete data were excluded and finally, 18 articles were enrolled. The flow diagram is shown in Fig 1.

thumbnail
Download:
Fig 1. Flow diagram of the study.

https://doi.org/10.1371/journal.pone.0297785.g001

thumbnail
Download:
Table 1. Search strategy for identifying studies.

https://doi.org/10.1371/journal.pone.0297785.t001

3.2. Characteristics and quality evaluation

Eighteen articles were included in the meta-analysis. The basic characteristics and quality evaluation of the studies are shown in Table 2. Among them, 17 articles had T2DM and HC groups, and 3 articles divided the T2DM group into two subgroups according to the presence of cognitive impairment. Of the 18 articles included, 13 were done in China, 2 in Japan, and 1 in each of the following countries (USA, Italy, and Turkey). The sample’s mean age was >18 years in 15 articles and >60 years in 3 articles. The diagnostic criteria of T2DM as recommended by the World Health Organization were adopted in 11 articles; whereas the American Diabetes Association was employed in 1 article, but the remaining articles were not mentioned. Measurement of BDNF using ELISA in 17 articles, but 1 article was not mentioned. All of the 18 included studies were cross-sectional studies. Based on the quality evaluation of AHRQ, 11 studies scored 8, 4 studies scored 7, 1 study scored 5, and 1 study scored 4.

thumbnail
Download:
Table 2. Basic characteristics of literature and literature quality evaluation form.

https://doi.org/10.1371/journal.pone.0297785.t002

3.3. Meta-analysis

We compared the BDNF level between T2DM and HC groups (P < 0.001, I2 = 99%), and between the T2DM with or without cognitive impairment groups (P < 0.001, I2 = 90%) using a random-effect model since the heterogeneity test showed the I2 value >50%.

Seventeen articles contained 2966 T2DM cases and 3580 HCs. The serum BDNF level in the T2DM group was significantly lower than that in the HC group [SMD: -2.04, z = 11.19, P < 0.001] (Fig 2A). The number of T2DM patients with or without cognitive impairment was 672 and 1913, respectively. The serum BDNF levels in T2DM with cognitive impairment group had a marginal difference from those without cognitive impairment [SMD: -2.59, z = 1.87, P = 0.06] (Fig 2B).

thumbnail
Download:
Fig 2. Forest plot showing a standard mean difference for the BDNF levels.

(A) The different BDNF levels between T2DM and HC. (B) The different BDNF levels in T2DM patients with or without cognitive impairment. Abbreviations: BDNF, brain-derived neurotrophic factor; T2DM, type 2 diabetes mellitus; HC, healthy controls.

https://doi.org/10.1371/journal.pone.0297785.g002

3.4. Sensitivity analysis

Sensitivity analyses were conducted to evaluate the robustness of the findings by excluding 1 study at a time to assess if the results were driven by any one study. The significance of the meta-analysis outcome for T2DM and HC group changed when ruling out any one of 6/17 studies and the results also changed in T2DM with or without cognitive impairment group after ruling out 1/3 study, suggesting the results were unstable.

3.5. Subgroup analysis

Subgroup analysis based on the BDNF measuring instruments (either China or USA) exhibited that there were significant differences in BDNF values between T2DM and HC (China: P = 0.05; USA: P < 0.001; Total: P < 0.001), with large heterogeneity (China: P < 0.001 and I2 = 100%; USA: P < 0.001 and I2 = 99%; Total: P < 0.001 and I2 = 99%) (Fig 3). Then, subgroup analysis was performed on the same instrument brand in China or the USA, respectively and similar results were observed (China: P <0.001; USA: P = 0.002; Total: P <0.001). The heterogeneity was only observed in the same brand from the USA, but not in the same brand from China [China: (P = 0.84 and I2 = 0%; USA: P < 0.001 and I2 = 98%; Total: P < 0.001 and I2 = 96%)] (Fig 4). Subgroup analysis based on ethnicity and population distribution presented that the BDNF values were significantly different, except for the European (Asian: P < 0.001; European: P = 0.59; Total: P < 0.001). In addition, there was significant difference in the adults in T2DM and HC, except for the aged (adults: P < 0.001; the aged: P = 0.25; Total: P < 0.001), and there were no marked decrease in heterogeneity (Asian: P < 0.001 and I2 = 99%; European: P < 0.001 and I2 = 99%; Total: P < 0.001 and I2 = 99%) (Adults: P < 0.001 and I2 = 99%; the aged: P = 0.03 and I2 = 80%; Total: P < 0.001 and I2 = 99%) (Figs 5 and 6).

thumbnail
Download:
Fig 3. Forest plot of subgroup analysis stratified by the BDNF measuring instruments brand China or USA.

https://doi.org/10.1371/journal.pone.0297785.g003

thumbnail
Download:
Fig 4. Forest plot of subgroup analysis stratified by the same brand of instrument from China or the USA.

https://doi.org/10.1371/journal.pone.0297785.g004

thumbnail
Download:
Fig 5. Forest plot of subgroup analysis stratified by the ethnicity Asian or European.

https://doi.org/10.1371/journal.pone.0297785.g005

thumbnail
Download:
Fig 6. Forest plot of subgroup analysis stratified by the population adults or the aged.

https://doi.org/10.1371/journal.pone.0297785.g006

3.6. Publication bias analysis

After Egger’s and Begg’s test, the studies of T2DM and HC group, T2DM with or without cognitive impairment group showed no significant publication bias (P = 0.606, P = 0.672; P = 0.202, P = 1.000).

4. Discussion

Our study is the first meta-analysis to evaluate the levels of serum BDNF in T2DM patients and HCs and compare the levels between T2DM patients with or without cognitive impairment. We found that the serum BDNF levels were lower in T2DM compared with HC. Furthermore, the serum BDNF levels had a decreasing tendency in T2DM patients with cognitive impairment compared with those without cognitive impairment.

The BDNF plays a key role in the pathophysiology of T2DM due to improving glucose metabolism and insulin sensitivity [44–46]. Previous studies have reported that T2DM patients exhibited significantly lower levels of serum BDNF compared with normal controls [27–32,43], which is consistent with our research. Additionally, the cerebral output of BDNF is inhibited under hyperglycemia, logically decreased serum BDNF may be detected in the uncontrolled T2DM patients [14]. This is in line with the findings that there is an inverse correlation between serum BDNF levels and long-standing diabetes, in males and aged T2DM patients [43]. Interestingly, upregulated serum BDNF levels in T2DM patients were also reported [33,34]. Such discrepancy is possibly related to physical exercise, obesity, and a balanced diet in T2DM patients [47–50]. In addition, the serum BDNF levels are increased in T2DM patients who received metformin treatment [3]. This may also link to a compensatory mechanism of serum BDNF release in T2DM [33], which is supported by the findings that the upregulated serum BDNF levels control blood glucose in newly diagnosed T2DM patients, but this control ability might be lost in a long term T2DM patients [35]. Our explanation is further supported by a resting state fMRI report showing enhanced functional connectivity of the left hippocampus (a major source of BDNF) with the left inferior frontal gyrus in the early stage of T2DM, which might contribute to adaptive compensation of hippocampal function [51]. Taken together, the serum BDNF could be a useful biological marker to monitor the development of T2DM and the cerebral impairment in T2DM.

T2DM has reduced the number of new neurons in the hippocampus, and hippocampal neurogenesis plays an important role in learning and memory function throughout life [52]. The Hippocampal perhaps regulates BDNF to provide neuroprotection and control of synaptic interactions [53–56]. In the present meta-analysis, the serum BDNF levels presented a decreasing tendency in T2DM patients with cognitive impairment compared with those patients without cognitive impairment. Such downregulation was also observed in Alzheimer’s disease, showing that the serum BDNF levels may be involved in the progression of cognitive impairment [57]. Such findings showed that serum BDNF levels may be involved in the progression of cognitive impairment in patients with T2DM. Thus, the reduction of BDNF might contribute to the neuropathophysiology of brain damage in T2DM, especially relating to cognitive impairment in T2DM.

However, substantial heterogeneity existed in the present meta-analysis. The heterogeneity could be generated from related factors, including the different brands of instruments for measuring BDNF, times and methods of blood collection, population distributions, and ethnicities. Such heterogeneity has been eliminated in the subgroup analysis by comparing the data from the same brands of instruments.

There are some limitations in the study. Firstly, the meta-analysis mostly included Chinese Han populations, which may not reflect the entire population/race. Secondly, different diagnostic criteria for diabetes were applied which might also compromise the data analysis. Although internationally recognized scales were utilized, the lack of a standard protocol for cognitive impairment could lead to inconsistent results.

In conclusion, the present meta-analysis suggests that the decrease in serum BDNF levels in T2DM patients has resolved the inconsistencies in previous studies. The serum BDNF levels in T2DM patients with cognitive impairment had a downward trend compared with those patients without cognitive impairment. Moreover, the reduction of serum BDNF may be a vital neuropathophysiological mechanism of cognitive impairment in T2DM patients.

References

  1. 1. Song X, Zhu Z, Qian X, Liu X, Chen S, Tang H. Multi-Omics Characterization of Type 2 Diabetes Mellitus-Induced Cognitive Impairment in the db/db Mouse Model. Molecules (Basel, Switzerland). 2022;27(6). pmid:35335269
  2. 2. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nature reviews Endocrinology. 2016;12(10):616–22. pmid:27388988
  3. 3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):405–12. pmid:10938048
  4. 4. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I, et al. A new look at painful diabetic neuropathy. Diabetes research and clinical practice. 2018;144:177–91. pmid:30201394
  5. 5. Dhaliwal J, Dhaliwal N, Akhtar A, Kuhad A, Chopra K. Tetramethylpyrazine Attenuates Cognitive Impairment Via Suppressing Oxidative Stress, Neuroinflammation, and Apoptosis in Type 2 Diabetic Rats. Neurochemical research. 2022;47(8):2431–44. pmid:35665448
  6. 6. Zhao Q, Niu Y, Matsumoto K, Tsuneyama K, Tanaka K, Miyata T, et al. Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain. BMC complementary and alternative medicine. 2012;12:188. pmid:23082896
  7. 7. Nooyens AC, Baan CA, Spijkerman AM, Verschuren WM. Type 2 diabetes and cognitive decline in middle-aged men and women: the Doetinchem Cohort Study. Diabetes care. 2010;33(9):1964–9. pmid:20519662
  8. 8. Antal B, McMahon LP, Sultan SF, Lithen A, Wexler DJ, Dickerson B, et al. Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses. eLife. 2022;11. pmid:35608247
  9. 9. Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes care. 2016;39(2):300–7. pmid:26681727
  10. 10. Mayeda ER, Whitmer RA, Yaffe K. Diabetes and cognition. Clinics in geriatric medicine. 2015;31(1):101–15. pmid:25453304
  11. 11. Troshneva AY, Ametov AS. Parkinson’s disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 2022;122(11. Vyp. 2):12–8.
  12. 12. Balaratnasingam S, Janca A. Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther. 2012;134(1):116–24. pmid:22281237
  13. 13. Wang J, Zhao X, He M. Is BDNF biological link between depression and type 2 diabetes mellitus? Medical hypotheses. 2012;79(2):255–8. pmid:22626954
  14. 14. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50(2):431–8. pmid:17151862
  15. 15. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience letters. 2002;328(3):261–4. pmid:12147321
  16. 16. Goren JL. Brain-derived neurotrophic factor and schizophrenia. Ment Health Clin. 2016;6(6):285–8. pmid:29955483
  17. 17. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, et al. Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7(1):15–20. pmid:20205668
  18. 18. Wilkinson ST, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018;241:514–8. pmid:30153634
  19. 19. Du B, Lian Y, Chen C, Zhang H, Bi Y, Fan C, et al. Strong association of serum GSK-3β/BDNF ratio with mild cognitive impairment in elderly type 2 diabetic patients. Curr Alzheimer Res. 2019;16(12):1151–60.
  20. 20. Wei C, Sun Y, Chen N, Chen S, Xiu M, Zhang X. Interaction of oxidative stress and BDNF on executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology. 2020;111:104473. pmid:31655452
  21. 21. Lee SJ, Baek JH, Kim YH. Brain-derived neurotrophic factor is associated with cognitive impairment in elderly Korean individuals. Clin Psychopharmacol Neurosci. 2015;13(3):283–7. pmid:26598587
  22. 22. Yin Y, Su X, Pan L, Li C. BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease-a meta-analysis. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2019;40(9):1901–7. pmid:31104169
  23. 23. Wang Q, Liu J, Guo Y, Dong G, Zou W, Chen Z. Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson’s disease: a meta-analysis. Braz J Med Biol Res. 2019;52(8):e8443. pmid:31365694
  24. 24. Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M. Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus. Journal of diabetes research. 2017;2017:14. pmid:29062839
  25. 25. Yamanaka M, Itakura Y, Ono-Kishino M, Tsuchida A, Nakagawa T, Taiji M. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. Journal of bioscience and bioengineering. 2008;105(4):395–402. pmid:18499057
  26. 26. Karczewska-Kupczewska M, Kowalska I, Nikołajuk A, Adamska A, Zielińska M, Kamińska N, et al. Circulating brain-derived neurotrophic factor concentration is downregulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes care. 2012;35(2):358–62. pmid:22210566
  27. 27. Zhen YF, Liu XY, Li YK, Fang H, Cassidy RM, Zhang XY. Association of brain-derived neurotrophic factor with cognitive function: An investigation of sex differences in patients with type 2 diabetes. Psychosomatic Medicine. 2019;81(6):488–94. pmid:31083054
  28. 28. Sun ZC, Yu J, Liu YL, Hong ZZ, Ling L, Li GQ, et al. Reduced serum levels of brain-derived neurotrophic factor are related to mild cognitive impairment in Chinese patients with type 2 diabetes mellitus. Annals of Nutrition and Metabolism. 2018;73(4):271–81. pmid:30308512
  29. 29. He M, Wang J. Decreased serum brain-derived neurotrophic factor in Chinese patients with Type 2 diabetes mellitus. Acta biochimica et biophysica Sinica. 2014;46(5):426–7. pmid:24777496
  30. 30. Guo M, Liu H, Li SS, Jiang FL, Xu JM, Tang YY. Low serum brain-derived neurotrophic factor but not brain-derived neurotrophic factor gene val66met polymorphism is associated with diabetic retinopathy in chinese type 2 diabetic patients. Retina (Philadelphia, Pa). 2017;37(2):350–8. pmid:27355244
  31. 31. Li B, Lang N, Cheng ZF. Serum levels of brain-derived neurotrophic factor are associated with diabetes risk, complications, and obesity: A cohort study from chinese patients with type 2 diabetes. Molecular neurobiology. 2016;53(8):5492–9. pmid:26454822
  32. 32. Murillo Ortiz B, Ramirez Emiliano J, Ramos-Rodriguez E, Martinez-Garza S, Macias-Cervantes H, Solorio-Meza S, et al. Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes. World journal of diabetes. 2016;7(20):615–20. pmid:28031779
  33. 33. Liu W, Han X, Zhou X, Zhang S, Cai X, Zhang L, et al. Brain derived neurotrophic factor in newly diagnosed diabetes and prediabetes. Molecular and cellular endocrinology. 2016;429:106–13. pmid:27062899
  34. 34. Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2006;55(7):852–7. pmid:16784955
  35. 35. Spartano NL, Davis-Plourde KL, Himali JJ, Murabito JM, Vasan RS, Beiser AS, et al. Self-reported physical activity and relations to growth and neurotrophic factors in diabetes mellitus: the framingham offspring study. Journal of diabetes research. 2019;2019:9. pmid:30729134
  36. 36. Sun Q, Tang DD, Yin EG, Wei LL, Chen P, Deng SP, et al. Diagnostic Significance of Serum Levels of Nerve Growth Factor and Brain Derived Neurotrophic Factor in Diabetic Peripheral Neuropathy. Med Sci Monit. 2018;24:5943–5950. pmid:30145601
  37. 37. Zheng TP, Liu H, Qin L, Chen B, Zhang X, Hu X, et al. Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metabolism. 2018;87:105–112. pmid:29572131
  38. 38. Ren QG, Chang JH, Lu WJ, Gong WG, Zhou H. Low plasma BDNF is not a biomarker for cognitive dysfunction in elderly T2DM patients. Neurol Sci. 2017;38(9):1691–1696. pmid:28681311
  39. 39. Liu W, Han X, Zhou X, Zhang S, Cai X, Zhang L, et al. Brain derived neurotrophic factor in newly diagnosed diabetes and prediabetes. Mol Cell Endocrinol. 2016;429:106–13. pmid:27062899
  40. 40. Wei H, Qu H, Wang H, Ji B, Deng H. Serum brain-derived neurotrophic factor levels and sleep disorders in Chinese healthy and newly diagnosed type 2 diabetic subjects. J Diabetes. 2017;9(2):180–189. pmid:27038292
  41. 41. Boyuk B, Degirmencioglu S, Atalay H, Guzel S, Acar A, Celebi A, et al. Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:978143. pmid:25587547
  42. 42. Passaro A, Dalla Nora E, Morieri ML, Soavi C, Sanz JM, Zurlo A, et al. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. J Gerontol A Biol Sci Med Sci. 2015;70(3):294–302. pmid:24621946
  43. 43. Fujinami A, Ohta K, Obayashi H, Fukui M, Hasegawa G, Nakamura N, et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clinical biochemistry. 2008;41(10–11):812–7. pmid:18402781
  44. 44. Yamanaka M, Tsuchida A, Nakagawa T, Nonomura T, Ono-Kishino M, Sugaru E, et al. Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Diabetes, obesity & metabolism. 2007;9(1):59–64. pmid:17199719
  45. 45. Nakagawa T, Tsuchida A, Itakura Y, Nonomura T, Ono M, Hirota F, et al. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes. 2000;49(3):436–44. pmid:10868966
  46. 46. Tsuchida A, Nakagawa T, Itakura Y, Ichihara J, Ogawa W, Kasuga M, et al. The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice. Diabetologia. 2001;44(5):555–66. pmid:11380073
  47. 47. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30(9):464–72. pmid:17765329
  48. 48. Rojas Vega S, Strüder HK, Vera Wahrmann B, Schmidt A, Bloch W, Hollmann W. Acute BDNF and cortisol response to low intensity exercise and following ramp incremental exercise to exhaustion in humans. Brain research. 2006;1121(1):59–65. pmid:17010953
  49. 49. Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N, et al. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry. 2003;54(4):485–90. pmid:12915293
  50. 50. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, et al. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free radical biology & medicine. 2007;42(5):665–74. pmid:17291990
  51. 51. Fang F, Lai MY, Huang JJ, Kang M, Ma MM, Li KA, et al. Compensatory hippocampal connectivity in young adults with early-stage type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2019;104(7):3025–38. pmid:30817818
  52. 52. Bonds JA, Shetti A, Stephen TKL, Bonini MG, Minshall RD, Lazarov O. Deficits in hippocampal neurogenesis in obesity-dependent and -independent type-2 diabetes mellitus mouse models. Scientific reports. 2020;10(1):16368. pmid:33004912
  53. 53. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth factors (Chur, Switzerland). 2004;22(3):123–31. pmid:15518235
  54. 54. Zaletel I, Filipović D, Puškaš N. Hippocampal BDNF in physiological conditions and social isolation. Rev Neurosci. 2017;28(6):675–92. pmid:28593903
  55. 55. Barreda Tomás FJ, Turko P, Heilmann H, Trimbuch T, Yanagawa Y, Vida I, et al. BDNF Expression in Cortical GABAergic Interneurons. Int J Mol Sci. 2020;21(5). pmid:32106593
  56. 56. Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cellular and molecular neurobiology. 2018;38(3):579–93. pmid:28623429
  57. 57. Siuda J, Patalong-Ogiewa M, Zmuda W, Targosz-Gajniak M, Niewiadomska E, Matuszek I, et al. Cognitive impairment and BDNF serum levels. Neurologia i neurochirurgia polska. 2017;51(1):24–32. pmid:28341039